Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30,099Revenue $M580Net Margin (%)-117.4Altman Z-Score11.8
Enterprise Value $M29,753EPS $-3.1Operating Margin %-108.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-117.0Higher ROA y-yN
Price/Book32.610-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales51.75-y EBITDA Growth Rate %--Current Ratio4.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-62.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M244ROIC % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2015-03-31 Reduce-0.08%$107.88 - $134.25
($119.81)
$ 131.2610%Reduce 2.80%9,533,911
VRTXGeorge Soros 2015-03-31 Buy 0.07%$107.88 - $134.25
($119.81)
$ 131.2610%New holding56,912
VRTXKen Fisher 2015-03-31 Add$107.88 - $134.25
($119.81)
$ 131.2610%Add 0.18%4,386
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 131.2617%Reduce 16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 131.2638%Reduce 31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 131.2687%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 131.2688%Sold Out0
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 131.2688%New holding6,753
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 131.2666%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 131.2666%New holding10,000
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 131.2689%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 131.2665%Add 19.00%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 131.2678%Add 140.58%5,990,000
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 131.2678%Sold Out0
VRTXVanguard Health Care Fund 2013-03-31 Add0.05%$43.65 - $54.97
($48.01)
$ 131.26173%Add 10.97%2,489,800
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 131.26174%Reduce 23.44%191,032
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 131.26145%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 131.26145%Sold Out0
VRTXNWQ Managers 2012-06-30 Reduce-0.27%$35.75 - $65.62
($50.92)
$ 131.26158%Reduce 83.86%188,842
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 131.26158%New holding20,025
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2015-07-01Sell11,700$125.64.51view
BOGER JOSHUA SDirector 2015-06-24Sell11,700$130.410.65view
BOGER JOSHUA SDirector 2015-06-17Sell11,700$123.95.94view
BOGER JOSHUA SDirector 2015-06-10Sell11,700$125.024.99view
BOGER JOSHUA SDirector 2015-06-03Sell11,700$125.814.33view
MCGLYNN MARGARET GDirector 2015-06-01Sell12,500$127.323.09view
BOGER JOSHUA SDirector 2015-05-27Sell11,700$126.084.11view
BOGER JOSHUA SDirector 2015-05-20Sell11,700$126.733.57view
Arbuckle Stuart AEVP\Chief Commercial Officer 2015-05-15Sell148$123.855.98view
SMITH IAN FEVP & CFO 2015-05-15Sell378$125.624.49view

Quarterly/Annual Reports about VRTX:

News about VRTX:

Articles On GuruFocus.com
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
What You May Have Missed in Biotech: Celgene's $1B Bet on Cancer Immunotherapy, and a New CF Drug Jul 03 2015
Vertex’s $259,000 Cystic Fibrosis Drug Gets FDA Approval Jul 02 2015
Business Highlights Jul 02 2015
Stock Pops & Drops: VRTX, HUM, WU & BP Jul 02 2015
ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the... Jul 02 2015
FDA clears drug for leading form of cystic fibrosis Jul 02 2015
FDA clears drug for leading form of cystic fibrosis Jul 02 2015
ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the... Jul 02 2015
Vertex's Orkambi Approved For CF, Prices On High Side Jul 02 2015
Vertex Pharmaceuticals: Now That's an Approval! Jul 02 2015
Trending Now: Vertex Pharmaceuticals Jul 02 2015
FDA approves new Vertex drug, stock halted Jul 02 2015
Vertex Pharma's lung disorder therapy wins FDA nod Jul 02 2015
Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo ORKAMBI Jul 02 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Other Events Jul 02 2015
Vertex Wins U.S. Approval for Cystic Fibrosis Combo Orkambi Jul 02 2015
Vertex Wins U.S. Approval for New Cystic Fibrosis Drug Jul 02 2015
Vertex gets FDA OK for cystic-fibrosis drug Jul 02 2015
FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of... Jul 02 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK